NCT04595474Active, not recruiting
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Patients With Type 1 Diabetes Using Vibration-Controlled Transient Elastography and Noninvasive Scores
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 533 (estimated)
- First submitted
- 13 Oct 2020
- Start date
- 14 Jan 2021
- Primary completion date
- 19 Aug 2022
- Lead sponsor
- Joslin Diabetes Center
- NCT number
- NCT04595474
What you commit to
- Study type: Observational
- Planned participants: 533
- From 14 Jan 2021 to the primary completion date, 19 Aug 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or previous use of any of the following medication: amiodarone, tamoxifen, methotrexate,corticosteroids (e.g. Prednisone), or Valproate
Other illness
- Subject has an active malignancy
- 4.Subject with secondary causes of fatty liver including history of any of the following:
- Hepatitis B or C virus infection
- Wilson's disease
Other
- Subject is pregnant or lactating
- Lipodystrophy
- Abetalipoproteinemia
- Male subject consuming \>30 g of alcohol per day or female subject consuming \>20 g of alcohol perday
Who the study is looking for
- Subject is male or female
- Subject age between 18-75 years old
- Subject with an established diagnosis of T1D for at least three months prior to screening
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Joslin Diabetes Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.